For example, enhanced Treg activity reported with anti-TNF use in RA – of potential concern in the context of a tumour microenvironment – was specifically linked to monoclonal antibody use rather than that of a receptor fusion protein (102), emphasising that the mechanism of action of targeted therapy may be as important as the molecular targets themselves in this setting. The gene discussed is TNF; the disease is rheumatoid arthritis.